



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 285/12, A61K 31/41, C07D 417/12, 417/14	A1	(11) International Publication Number: WO 99/20617 (43) International Publication Date: 29 April 1999 (29.04.99)
(21) International Application Number: PCT/US98/21630 (22) International Filing Date: 20 October 1998 (20.10.98) (30) Priority Data: 60/062,768 21 October 1997 (21.10.97) US (71) Applicant (for all designated States except US): PHARMACIA & UPJOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GAMMILL, Ronald, B. [US/US]; 38 Village Drive, East Lyme, CT 06333 (US). VANDER VELDE, Susan [US/US]; 6125 Fairgrove, Kalamazoo, MI 49009 (US). MITCHELL, Mark, Allen [US/US]; 1628 Dover Road, Kalamazoo, MI 49008 (US). NUGENT, Richard, Allen [US/US]; 11358 East HJ Avenue, Galesburg, MI 49053 (US). (74) Agent: YANG, Lucy, X.; Pharmacia & Upjohn Company, Intellectual Property Legal Services, 301 Henrietta Street, Kalamazoo, MI 49001 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTINFLAMMATORY THIADIAZOLYL UREAS WHICH ACT AS LFA-1 AND MAC-1 INHIBITORS <div style="text-align: center;"> <p>(I)</p> </div> (57) Abstract <p>The present invention provides a compound of formula (I) wherein R₁, R₂ and R₃ are as defined herein. The compounds of the present invention are therapeutically useful in the treatment of a broad range of inflammatory disease such as, for example, hypersensitivity reactions, asthma, rheumatoid arthritis, bacterial meningitis, aspiration lung injury, inflammatory bowel disorder and related complications.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANTIINFLAMMATORY THIADIAZOLYL UREAS WHICH ACT AS LFA-1 AND MAC-1 INHIBITORS

FIELD OF THE INVENTION

This invention relates to novel thiadiazole ureas, to pharmaceutical
5 compositions containing them, and to methods of using them. The compounds of the
invention are pharmaceutically active in the treatment of inflammatory diseases.

BACKGROUND OF THE INVENTION

Inflammation is an integral part of a wide array of human diseases, ranging
10 from bacterial pneumonia, in which the response is life-saving, to adult respiratory
distress syndrome, in which it is life-threatening. Inflammation may result in
substantial tissue damage or initiate processes leading to excessive fibrous repair,
and therefore it is desirable to interrupt its progression. Today, many investigators
are attempting to identify new therapeutic agents designed to directly block
15 adhesive events involved in an array of disease processes.

LFA-1 and Mac-1, members of the $\beta 2$ integrin family of adhesion molecules,
are thought to play a critical role in several types of inflammatory disease processes
by interacting with intercellular adhesion molecule (ICAM), which promotes the
migration of the leukocyte rapidly into surrounding tissue. Support for the
20 importance of $\beta 2$ integrin in mediating inflammatory responses has been
demonstrated by the evidence that transendothelial migration *in vitro* is markedly
inhibited by monoclonal antibodies against $\beta 2$ integrins or ICAM-1. C. W. Smith,
Can. J. Physiol. Pharmacol., Vol. 71, pp 76-87 (1993). Furthermore, blockade of the
LFA-1 complex has been shown to inhibit neutrophil influx in almost every system,
25 including skin, peritoneum, synovium, lung, kidney, and heart. As one of the
primary ligands for the $\beta 2$ integrins, it would also be expected that blockade of
ICAM-1 would inhibit the inflammatory response. S. M. Albelda et al., *The FASEB*
J., Vol. 8, pp 504-512 (1994).

We now have discovered that certain novel thiadiazole ureas are LFA-1 and
30 Mac-1 inhibitors. Molecules that inhibit LFA-1 and Mac-1 binding with ICAM-1
down regulate inappropriate leukocyte wreaking havoc on healthy tissues seen in
acute and chronic inflammatory diseases. As such, these compounds of the present
invention are therapeutically useful in the treatment of a broad range of
inflammatory disease such as, for example, hypersensitivity reactions, asthma,
35 rheumatoid arthritis, bacterial meningitis, aspiration lung injury, inflammatory
bowel disorder and related complications.

INFORMATION DISCLOSURE

The following references disclose thiadiazole derivatives.

International Publication No. WO 96/30370 discloses thiazole and thiadiazole derivatives useful in the treatment of thrombocytopenia.


- 5 U. S. Patent 4,775,408 discloses pyridine substituted thiadiazole ureas which have herbicidal and plant growth regulatory properties.

U. S. Patent 4,576,629 discloses herbicidal thiadiazole ureas wherein the 5-position of the thiadiazole ring is hetero substituted and which exhibit enhanced selective herbicidal activity.

- 10 Abstract of Japanese Patent 1160-976-A discloses 1,3,4-thiadiazole derivatives useful as antiulcer agents.

SUMMARY OF THE INVENTION

The present invention presents novel compounds of formula I




I

or pharmaceutically acceptable salts thereof wherein:

R₁ is

- 10 a) -aryl,
 b) -aryl wherein aryl is substituted with one to three R₄,
 c) -Q,
 d) -Q wherein Q is substituted with one to three R₄,
 e) -Het,
 15 f) -Het wherein Het is substituted with one to three R₄,



20

- h) , optionally substituted with C₁₋₄ alkyl or C₃₋₆ cycloalkyl,

- i) C_{1-6} carboalkoxy,
 - j) $-C(=O)-CH_2CO_2(C_{1-4} \text{ alkyl})$,
 - k) $-C(=O)NH(CH_2)_jR_5$,
 - l) C_{1-10} alkyl,
 - 5 m) C_{1-10} alkyl substituted with one to three R_6 ,
 - n) C_{1-10} alkenyl, or
 - o) C_{1-10} alkenyl substituted with one to three R_6 ;
- R_2 is
- 10 a) $-(CH_2)_j(CR_7R_8)_k-$;
- R_3 is
- a) $-(CR_9R_{10})_l(CH_2)_f\text{-aryl}$,
 - b) $-(CR_9R_{10})_l(CH_2)_f\text{-aryl}$ wherein aryl is substituted with one to three R_{11} ,
 - 15 c) $-(CR_9R_{10})_l(CH_2)_f\text{-Q}$,
 - d) $-(CR_9R_{10})_l(CH_2)_f\text{-Q}$ wherein Q is substituted with one to three R_{11} ,
 - e) $-(CR_9R_{10})_l(CH_2)_f\text{-Het}$,
 - f) $-(CR_9R_{10})_l(CH_2)_f\text{-Het}$ wherein Het is substituted with one to three R_{11} , or
 - 20 g) $-(CR_9R_{10})_l\text{-}(CH_2)_f\text{-pentafluorophenyl}$;
- R_4 is
- a) halo,
 - b) C_{1-4} alkyl,
 - c) C_{3-6} cycloalkyl,
 - 25 d) C_{1-4} alkoxy,
 - e) aryl,
 - f) Q,
 - g) Het,
 - h) C_{1-4} carboalkoxy,
 - 30 i) C_{1-4} monoalkylamino,
 - j) C_{1-4} dialkylamino,
 - k) amido,
 - l) C_{1-4} alkylthio,
 - m) trihalomethyl,
 - 35 n) $-(CH_2)_l\text{-O-}(C_{1-4} \text{ alkyl})$,
 - o) nitro,

- p) mercapto,
 q) nitrine,
 r) cyano,
 s) hydroxy.
 5 t) $\text{-NHC(=O)(C}_{1-4}\text{ alkyl)}$, or
 u) $\text{-NHSO}_2(\text{C}_{1-4}\text{ alkyl})$;

R_5 is

- a) C_{1-8} alkyl,
 b) aryl,
 10 c) Q, or
 d) Het;

R_6 is

- a) halo,
 b) hydroxy,
 15 c) C_{1-4} alkoxy,
 d) C_{1-4} carboalkoxy,
 e) amido,
 f) nitro,
 g) trihalomethyl,
 20 h) cyano,
 i) mercapto,
 j) C_{1-4} alkylthio, or
 k) C_{1-8} alkyl;

R_7 and R_8 are the same and different and are

- 25 a) H,
 b) C_{1-6} alkyl,
 c) C_{3-6} cycloalkyl,
 d) $\text{-(CH}_2)_l\text{-O-C}_{1-4}\text{ alkyl}$,
 e) $\text{-(CH}_2)_l\text{-Q}$, or
 30 f) $\text{-(CH}_2)_l\text{-Het}$;

R_9 and R_{10} are the same and different and are

- a) H,
 b) C_{1-4} alkyl,
 c) C_{1-4} alkoxy,
 35 d) C_{3-6} cycloalkyl, or
 e) C_{1-4} carboalkoxy;

R₁₁ is

- a) C₁₋₄ alkyl,
- b) C₁₋₄ alkoxy,
- c) trihalomethyl,
- 5 d) halo,
- e) nitro,
- f) cyano,
- g) nitrine,
- h) C₁₋₄ acyl,
- 10 i) C₁₋₄ carboalkoxy, or
- j) carboxyl;

aryl is monocarbocyclic, or bicarbocyclic aromatic moiety;

Q is 5- to 10-membered saturated heterocyclic moiety having one to three atoms selected from the group consisting of oxygen, nitrogen, and sulfur;

- 15 Het is 5- to 10-membered unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of oxygen, nitrogen, and sulfur;

j is 0, 1, 2 or 3;

k is 0, 1, 2, 3, 4, 5 or 6;

l is 0, 1, 2, 3, 4 or 5;

- 20 *n* is 0, 1 or 2; and with the following provisos:

- a) where R₃ is a), R₁ is other than c) through f);
- b) where R₃ is aryl substituted with cyano, R₁ is other than phenyl substituted with cyano, unsubstituted pyridyl, furyl and -C(=O)-NHCH₂-pyridyl.

- The compounds of the present invention are therapeutically useful in the
- 25 treatment of a broad range of inflammatory disease such as, for example, hypersensitivity reactions, asthma, rheumatoid arthritis, bacterial meningitis, aspiration lung injury, inflammatory bowel disorder and related complications.

DETAILED DESCRIPTION OF THE INVENTION

- 30 For the purpose of the present invention, the carbon content of various hydrocarbon containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix C_{i-j} defines the number of carbon atoms present from the integer "i" to the integer "j", inclusive. Thus, for example, C₁₋₄ alkyl refers to alkyl of one to four carbon atoms, inclusive, or
- 35 methyl, ethyl, propyl, butyl and isomeric forms thereof.

The terms "C₁₋₄ alkyl", "C₁₋₆ alkyl", "C₁₋₈ alkyl", and "C₁₋₁₀ alkyl" refer to an

alkyl group having one to four, one to six, one to eight, or one to ten carbon atoms respectively such as, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and their isomeric forms thereof.

5 The term "C₂₋₁₀ alkenyl" refers to at least one double bond alkenyl group having two to ten carbon atoms respectively such as, for example, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, heptdienyl, octenyl, octadienyl, octatrienyl, nonenyl, undecenyl, dodecenyl, and their isomeric forms thereof.

10 The term "C₃₋₆ cycloalkyl" refers to a cycloalkyl having three to six carbon atoms such as, for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl and their isomeric forms thereof.

The terms "C₁₋₄ alkoxy" refers to an alkyl group having one to four carbon atoms attached to an oxygen atom of hydroxyl group such as, for example, methoxy, ethoxy, propyloxy, butyloxy and their isomeric forms thereof.

15 The term "C₁₋₄ alkylthio" refers to an alkyl group having one to four carbon atoms attached to a thiohydroxy moiety, for example, methylthio, ethylthio, propylthio, butylthio and isomeric forms thereof.

The terms "C₁₋₄ acyl" and "C₁₋₆ acyl" refer to a carbonyl group having an alkyl group of one to four or one to six carbon atoms respectively.

20 The terms "C₁₋₄ carboalkoxy" and "C₁₋₆ carboalkoxy" refer to an ester group having an alkyl group of one to four or one to six carbon atoms respectively.

The term "C₁₋₄ monoalkylamino" refers to an alkyl group having one to four carbon atoms attached to an amino moiety, for example, methylamine, ethylamine, n-propylamine, n-butylamine, and isomeric forms thereof.

25 The term "C₁₋₄ dialkylamino" refers to two alkyl groups having one to four carbon atoms attached to an amino moiety, for example, dimethylamine, methylethylamine, diethylamine, dipropylamine, methypropylamine, ethylpropylamine, dibutylamine, and isomeric forms thereof.

The term "halo" refers to fluoro, chloro, bromo, or iodo.

30 The term trihalomethyl refers to trifluoromethyl, trichloromethyl or tribromomethyl.

The term "aryl" refers to monocarbocyclic or bicarbocyclic aromatic moiety such as, for example phenyl, naphthyl or biphenyl. Each of these moieties may be substituted as appropriate. Aryl is preferably substituted and unsubstituted phenyl.

35 The term "Het" refers to a 5- to 10-membered unsaturated heterocyclic moiety having one or more atoms selected from the group consisting of oxygen, nitrogen, and sulfur such as; for example, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-

pyrimidinyl, 5-pyrimidinyl, 3-pyridazinyl, 4-pyridazinyl, 3-pyrazinyl, 2-quinolyl, 3-quinolyl, 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 2-quinazolinyl, 4-quinazolinyl, 2-quinoxaliny, 1-phthalazinyl, 2-imidazolyl, 4-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isothiazole, 4-isothiazole, 5-isothiazole, 2-indolyl, 3-indolyl, 3-indazolyl, 2-benzoxazolyl, 2-benzothiazolyl, 2-benzimidazolyl, 2-benzofuranyl, 3-benzofuranyl, benzoisothiazole, benzoisoxazole, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isopyrrolyl, 4-isopyrrolyl, 5-isopyrrolyl, 1-indolyl, 1-indazolyl, 2-isoindolyl, 1-purinyl, 3-isothiazolyl, 4-isothiazolyl and 5-isothiazolyl, preferably pyridyl, quionlinyl, pyrrolyl, thienyl, thiazolyl, or indolyl.

The term "Q" refers to a 5- to 10-membered saturated heterocyclic moiety having one to two atoms selected from the group consisting of oxygen, nitrogen, and sulfur such as, for example, piperidinyl, 2-, 3-, or 4-piperidinyl, [1,4]piperazinyl, morpholinyl, 2- or 3-morpholinyl, thiomorpholinyl, dioxolanyl, imidazolidinyl, [1,3]oxathiolanyl, [1,3]oxazolidinyl, pyrrolidinyl, butyrolactonyl, butyrolactamyl, succinimidyl, glutarimidyl, valerolactamyl, 2,5-dioxo-[1,4]-piperazinyl, pyrazolidinyl, 3-oxopyrazolidinyl, 2-oxo-imidazolidinyl, 2,4-dioxo-imidazolidinyl, 2-oxo-[1,3]-oxazolidinyl, 2,5-dioxo-[1,3]-oxazolidinyl, isoxazolidinyl, 3-oxo-isoxazolidinyl, [1,3]-thiazolidinyl, 2- or 4-oxo-[1,3]-thiazolidinyl, butyrolactamyl, succinimidyl, glutarimidyl, valerolactamyl, 2,5-dioxo-[1,4]-piperazinyl, 3-oxopyrazolidinyl, 2-oxo-imidazolidinyl, 2,4-dioxo-imidazolidinyl, 2-oxo-[1,3]-oxazolidinyl, 2,5-dioxo-[1,3]-oxazolidinyl, 3-oxo-isoxazolidinyl, 2- or 4-oxo-[1,3]-thiazolidinyl.

Within the definition of the terms "Het" and "Q", the nitrogen atom forming the hetero rings may have a protective group such as an acetyl or hydroxyacetyl group.

Certain reagents are abbreviated herein. THF refers to tetrahydrofuran, DMF refers to dimethyl formamide.

The compounds of the present invention can be converted to their salts, where appropriate, according to conventional methods.

The term "pharmaceutically acceptable salts" refers to addition salts useful for administering the compounds of this invention and include hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate, acetate, propionate, lactate, mesylate, maleate, malate, succinate, tartrate, citric acid, 2-hydroxyethyl sulfonate, fumarate and the like. These salts may be in hydrated form. Some of the compounds of this invention may form metal salts such as sodium, potassium, calcium and magnesium salts and these are embraced by the term

"pharmaceutically acceptable salts".

Depending on substituents, the compounds of formula I of this invention may contain a chiral center and other isomeric forms and this invention embraces all possible stereoisomers and geometric forms.

- 5 Typical antiinflammatory thiadiazoles ureas and amides of this invention are
- a N-[5-[(3,5-Dimethoxyphenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- b N-[5-[(4-Methoxyphenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- 5 c N-[5-[(3,4-Dimethoxyphenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- d N-[5-[[6-(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)hexyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- e N-[5-[(1,1'-Biphenyl)-4-ylmethyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- 10 f (E)-N-[5-[(3,7-Dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- g (E)-N-[5-[(3,7-Dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- 15 h (E)-N-[5-[(3,7-Dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[1-(2-naphthalenyl)ethyl]urea,
- i N-(2-Phenylethyl)-N'-[5-[(phenylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- j Methyl [[5-[[[(2-phenylethyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]acetate,
- 20 k Methyl [[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]acetate,
- l t-Butyl [[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]acetate,
- m Methyl 3-[[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,
- 25 n Methyl 3-[[[5-[[[(2-trifluoromethylphenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,
- o Methyl 3-[[[5-[[[(3-trifluoromethylphenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,
- 30 p Methyl 3-[[[5-[[[(4-trifluoromethylphenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,


- q 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-octylacetamide,
- r N-(3-Cyanophenyl)-N'-[5-[(2-fluoro-4-nitrophenyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- 5 s N-[5-[(Cyanomethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- t N-(3-Cyanophenyl)-N'-[5-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- u N-(3-Cyanophenyl)-N'-[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- v Methyl 4-[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-3-oxobutanoate,
- 10 w N-(3-cyanophenyl)-N'-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- x N-[5-[(5-Cyanopentyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- y N-[5-[[[(4-Chloro-2-nitrophenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- 15 z N-(3-Cyanophenyl)-N'-[5-(2-propenylthio)-1,3,4-thiadiazol-2-yl]urea,
- aa N-(3-Cyanophenyl)-N'-[5-(2-propynylthio)-1,3,4-thiadiazol-2-yl]urea,
- bb N-(3-cyanophenyl)-N'-[5-(octylthio)-1,3,4-thiadiazol-2-yl]urea,
- cc Methyl 3-[[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio)methyl]benzoate,
- 20 dd Methyl 3-[[[5-[[[(2-phenylethyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio)methyl]benzoate,
- ee N-[5-[(3-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- ff N-[5-[(4-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- 25 gg N-(3-Fluorophenyl)-N'-[5-[(2-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- hh N-(3-Fluorophenyl)-N'-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- ii N-(3-Fluorophenyl)-N'-[5-[(4-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- jj 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(2-methoxyethyl)acetamide,
- 30 kk 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(2-pyridinylmethyl)acetamide,
- ll 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(4-pyridinylmethyl)acetamide,
- 35 mm N-(2-Phenylethyl)-N'-[5[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- nn N-(2-Phenylethyl)-N'-[5[(2-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,

- oo (E)-N-(3-Acetylphenyl)-N'-[5-[(3,7-dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- pp 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-phenylacetamide,
- 5 qq N-(3-Fluorophenyl)-N'-[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- rr N-[5-[(2-Quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- ss 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-2-propenylacetamide,
- 10 tt 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(phenylmethyl)acetamide,
- uu 1,1-Dimethylethyl 5-[[[5-[[[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]-2-thiophenecarboxylate,
- vv N-(3-Cyanophenyl)-N'-[5-[[[(1-cyclohexyl-1H-tetrazol-5-yl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 15 ww 1,1-Dimethylethyl 3-[[[5-[[[(3-fluorophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,
- xx 1,1-Dimethylethyl 3-[[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,
- 20 yy N-(3-Cyanophenyl)-N'-[5-[[[1-(3-methylfuro[2,3-c]pyridin-5-yl)ethyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- zz N-(3-Cyanophenyl)-N'-[5-[[[4-(1-methylethyl)-2-pyridinyl]methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- aaa N-(3-Fluorophenyl)-N'-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- 25 bbb N-(3-Fluorophenyl)-N'-[5-[(3-furanylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- ccc N-[[[5-[(2-Quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]-L-phenylalanine ethyl ester,
- ddd N-[5-[(2-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- 30 eee N-[5-[(3-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- fff N-[5-[(4-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- ggg N-(3-Chlorophenyl)-N'-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- 35 hhh N-(3,5-Dichlorophenyl)-N'-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,


- iii N-(3-Cyanophenyl)-N'-[5-[[1-[5-(1-methylethyl)-3-pyridinyl]ethyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- iii N-(3-Fluorophenyl)-N'-[5-[[[5-phenyl-3-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 5 kkk N-(3-Fluorophenyl)-N'-[5-[[1-(phenylmethyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- lll N-[5-[(Cyclopropylphenylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-fluorophenyl)urea,
- mmm N-(3-Fluorophenyl)-N'-[5-[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 10 nnn N-(3-Fluorophenyl)-N'-[5-[(1-phenylbutyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- ooo N-(3-Fluorophenyl)-N'-[5-[[1-(2-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- ppp N-(3-Fluorophenyl)-N'-[5-[[1-(4-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 15 qqq N-(3-Fluorophenyl)-N'-[5-[[[5-(3-thienyl)-3-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- rrr Ethyl 3-[[[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]benzoate,
- 20 sss 3-[[[5-[(1-Phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]benzoic acid,
- ttt N-(3-Chlorophenyl)-N'-[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- uuu Ethyl 3-[[[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]benzoate,
- 25 vvv N-[5-[(2-Quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-3,5-bis(trifluoromethyl)benzamide,
- www N-[5-[[1-[3-(Acetylamino)phenyl]ethyl]thio]-1,3,4-thiadiazol-2-yl]-3,4-dichlorobenzamide,
- xxx N-[3-[1-[[5-[[[5-(3-Fluorophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]ethyl]phenyl]methanesulfonamide,
- 30 yyy N-[5-[[1-(3-Azidophenyl)ethyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(3-fluorophenyl)urea,
- zzz N-[5-[[1-(3-Azidophenyl)ethyl]thio]-1,3,4-thiadiazol-2-yl]-3,4-dichlorobenzamide,
- 35 aaaa 3-Azido-4-chloro-N-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]benzamide,
- bbbb 3-Azido-6-chloro-N-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]benzamide,

cccc 2,6-Difluoro-N-[5-[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]benzamide,
 dddd N-(3-Fluorophenyl)-N'-[5-[[1-(4-fluorophenyl)ethyl]thio]-1,3,4-thiadiazol-2-yl]urea, and
 eeee N-(3-Azido-4-fluorophenyl)-N'-[5-[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea.

The compounds of formula I are generally prepared by coupling an alkylating agent A




with commercially available 5-amino-1,2,5-thiadiazole-2-thiol in the presence of appropriate base such as, for example, triethylamine or sodium hydride. R' is R_1 - R_2 - radical as defined previously and halo is fluoro, chloro, bromo or iodo. The alkylating agents A are either commercially available or can be prepared from the corresponding alcohols with an activating agents such as methanesulfonyl chloride or thionyl chloride. The coupling results in the formation of the intermediate B:



in the presence of an appropriate solvent such as, for example, THF, EtOAc, DMF, CH_3Cl or CH_3CN at room or slightly elevated temperature.

Particularly useful starting compounds in the preparation of compounds of formula I of the present invention is a compound of formula D:



wherein R_4 is as defined previously, R'' is R_7 or R_8 are as defined previously, the ring E is aryl, Q or Het as defined previously. All these starting compounds are either commercially available or can be easily prepared according to the methods well known in the art. Some of the starting compounds preparations are illustrated in Examples as described hereinafter.

To provide compounds of formula I of the present invention, the intermediate B is converted to the corresponding thiadiazoles ureas by addition of isocyanate, $R_3-N=C=O$, in an appropriate solvent such as THF. The methods of these reactions are well known to those skilled in the art.

When desirable, the sulfur atom of the side chain can be oxidized by an appropriate oxidizer using the methods well known to those skilled in the art in an early synthetic step or at the end of synthetic sequence to the corresponding sulfones and sulfoxides, respectively.

5 The pharmaceutical compositions of this invention may be prepared by combining the compounds of formula I of this invention with a solid or liquid pharmaceutically acceptable carrier, and optionally, with pharmaceutically acceptable adjuvants and excipients employing standard and conventional techniques. Solid form compositions include powders, tablets, dispersible granules, 10 capsules and suppositories. A solid carrier can be at least one substance which may also function as a diluent, flavoring agent, solubilizer, lubricant, suspending agent, binder, tablet disintegrating agent, and encapsulating agent. Inert solid carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, cellulosic materials, low melting wax, cocoa butter, and the 15 like. Liquid form compositions include solutions, suspensions and emulsions. For example, there may be provided solutions of the compounds of this invention dissolved in water, water-propylene glycol, and water-polyethylene glycol systems, optionally containing conventional coloring agents, flavoring agents, stabilizers and thickening agents.

20 The pharmaceutical composition is provided by employing conventional techniques. Preferably the composition is in unit dosage form containing an effective amount of the active component, that is, the compounds of formula I according to this invention.

 The quantity of active component, that is, the compounds of formula I 25 according to this invention, in the pharmaceutical composition and unit dosage form thereof may be varied or adjusted widely depending upon the particular application method, the potency of the particular compound and the desired concentration. Generally, the quantity of active component will range between 0.5% to 90% by weight of the composition.

30 In therapeutic use for treating inflammatory complications in humans and other animals that have been diagnosed with inflammatory disease, the compounds or pharmaceutical compositions thereof will be administered orally, parenterally, aerosol, and/or topically at a dosage to obtain and maintain a concentration, that is, an amount, or blood-level of active component in the animal undergoing treatment 35 which will be antiinflammatory effective. Generally, such antiinflammatory effective amount of dosage of active component will be in the range of about 0.1 to about 200

mg/kg, more preferably about 3.0 to about 50 mg/kg of body weight/day. It is to be understood that the dosages may vary depending upon the requirements of the patient, the severity of the inflammatory complication being treated, and the particular compounds being used. Also, it is to be understood that the initial dosage administered may be increased beyond the above upper level in order to rapidly achieve the desired blood-level or the initial dosage may be smaller than the optimum and the daily dosage may be progressively increased during the course of treatment depending on the particular situation. If desired, the daily dose may also be divided into multiple doses for administration, e.g., two to four times per day.

- 10 These compounds are useful for the treatment of inflammatory complications in humans and other warm blooded animals by either parenteral, oral, aerosol, or topical administration. In general, the preferred form of administration is orally. Pharmaceutical compositions for parenteral administration will generally contain a pharmaceutically acceptable amount of the compounds according to formula I as a
- 15 soluble salt (acid addition salt or base salt) dissolved in a pharmaceutically acceptable liquid carrier such as, for example, water-for-injection and a suitably buffered isotonic solution having a pH of about 3.5 - 6. Suitable buffering agents include, for example, trisodium orthophosphate, sodium bicarbonate, sodium citrate, N-methylglucamine, L(+)-lysine and L(+)-arginine, to name a few. The compounds
- 20 according to formula I generally will be dissolved in the carrier in an amount sufficient to provide a pharmaceutically acceptable injectable concentration in the range of about 1 mg/ml to about 400 mg/ml. The resulting liquid pharmaceutical composition will be administered so as to obtain the above mentioned antiinflammatory effective amount of dosage. The compounds of formula I according
- 25 to this invention are advantageously administered orally in solid and liquid dosage forms.

- The compounds of this invention are useful antiinflammatory agents, effective against a broad range of inflammatory disease states in which neutrophils wreak havoc on healthy tissues. Therefore, they are therapeutically useful in the
- 30 treatment of chronic or acute inflammatory disease such as, for example, hypersensitivity reactions, asthma, rheumatoid arthritis, bacterial meningitis, aspiration lung injury, inflammatory bowel disorder and related complications. Humans or animals suffered with such complications are readily diagnosed by a physician or veterinarian of ordinary skill.

- 35 The compounds and their preparations of the present invention will be better understood in connection with the following examples, which are intended as an

illustration of and not a limitation upon the scope of the invention.

I. Preparation of intermediate Compound B.

Method A:

- 5 5-Amino-1,3,4-thiadiazole-2-thiol (1 equiv.) is partially dissolved in CH_3CN . Triethylamine (2-3 equiv.) is added, followed by the alkyl chloride. The chloride is either commercially available, or generated from the alcohol with thionyl chloride (2 equiv.) in chloroform. The excess thionyl chloride is removed under reduced pressure, and the neat alkyl chloride was then added to the thiadiazole in CH_3CN .
- 10 The reaction is stirred at 25-65 °C overnight. The CH_3CN is removed *in vacuo*, and the residual oil is partitioned between CHCl_3 and H_2O . After the layers are separated, the aqueous phase is extracted with CHCl_3 . The combined organics are washed with brine, dried over MgSO_4 , and concentrated to crude material. Product is purified by either recrystallization or flash chromatography.

15 Method B:

- The mesylate of the appropriate alcohol is prepared *in situ*. The alcohol (1 equiv.) is dissolved in THF, and triethylamine (2 equiv.) is added. The reaction is cooled to 0 °C, and methanesulfonyl chloride (1.1 equiv.) is added. The reaction is allowed to warm to room temperature. After 1 hour, 5-amino-1,3,4-thiadiazole-2-
- 20 thiol (1 equiv.) is added. The reaction is stirred overnight. The reaction is diluted with EtOAc and H_2O . After separation, the aqueous phase is extracted with EtOAc. The combined organics are washed with brine, dried over MgSO_4 , and concentrated to crude material. Product is purified by flash chromatography or recrystallization.

Method C:

- 25 5-Amino-1,3,4-thiadiazole-2-thiol (1 equiv.) is dissolved in DMF and cooled to 0 °C. Sodium hydride (1.1 equiv) is added, and the reaction is stirred at 0 °C until all the solids are dissolved (1-2 hours). The alkyl chloride is generated from the alcohol (1 equiv.) with thionyl chloride (2 equiv.) in chloroform. The excess thionyl chloride is removed *in vacuo*. The alkyl chloride is added to the sodium anion of the
- 30 thiadiazole. The reaction is allowed to warm to room temperature and stirred for 5-12 hours. The reaction is quenched and then diluted with H_2O . The aqueous solution is extracted with EtOAc, and the combined organics are washed with brine. After drying over MgSO_4 , solvent is removed *in vacuo* to yield crude material. The product is purified by flash chromatography or recrystallization.

35 Method D:

 The appropriate alcohol (1 equiv.) and triethylamine (1.1 equiv.) is dissolved

in THF and cooled to 0 °C. Methanesulfonyl chloride (1.1 equiv.) is then added, and the reaction is stirred at room temperature for 1 hour. The reaction is diluted with EtOAc and H₂O, and the layers are separated. The organic phase is washed with brine and dried over MgSO₄. The solvent is removed *in vacuo*, yielding pale yellow oil. The mesylate is added neat to the sodium anion of the thiadiazole. The thiadiazole is deprotonated by added sodium hydride (1.1 equiv.) to a 0 °C solution of 5-amino-1,3,4-thiadiazole-2-thiol (1 equiv.) dissolved in DMF. The reaction is allowed to warm to room temperature and stirred overnight. The reaction is quenched and diluted with H₂O. The aqueous phase is extracted with EtOAc, and the combined organics are washed with brine. After drying over MgSO₄, the solvent is removed *in vacuo* yielding crude material. The product is isolated by flash chromatography or recrystallization.


II. Preparation of Thiadiazoles Ureas.

Method E:

To a solution (or slurry) of alkylated thiadiazole (1 equiv.) in THF is added the desired isocyanate (1.1 equiv.). The reaction is stirred at room temperature for 5-12 hours. The solvent is removed *in vacuo*. The product is purified by flash chromatography or recrystallization.

EXAMPLE 1

Preparation of N-(3-fluorophenyl)-N'-[5[(2-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.



Step 1 Preparation of 5-[(2-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method A and making non-critical variations but starting with 2-picolyl chloride HCl and 2-amino-5-mercapto-1,3,4-thiadiazole, the title compound is obtained as a solid. mp 147-9 °C.

¹H NMR (DMSO) δ 4.37, 7.26, 7.40, 7.74, 8.48.

IR (mull) 3307, 3265, 3087, 3016, 2435, 2322, 2257, 2155, 20, 68, 1650, 1499, 1431, 1405, 1051, 671, cm⁻¹.

Anal. Calcd for C₈H₈N₄S₂: C, 42.84; H, 3.60; N, 24.98.

Found: C, 42.66; H, 3.69; N, 24.90.

Step 2 Preparation of N-(3-fluorophenyl)-N'-[5[(2-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 1, the title compound is obtained as a solid. mp 202-204 °C.

¹H NMR (DMSO) δ 4.54, 6.80-6.89, 7.16-7.20, 7.28-7.34, 7.42-7.49, 7.74-7.81, 8.50-8.54, 9.29, 11.21.


¹³C NMR (DMSO) δ 105.4, 105.7, 109.2, 109.5, 114.6, 122.6, 123.1, 130.3, 130.5, 137.0, 149.1, 156.1, 160.6, 163.8.

IR (mull) 3368, 1959, 1924, 1709, 1614, 1604, 1568, 1554, 1495, 1481, 1444, 1430, 1403, 1315, 1226, cm⁻¹.

Anal. Calcd for C₁₅H₁₂FN₅OS₂: C, 49.85; H, 3.35; N, 19.38.

Found: C, 49.76; H, 3.49; N, 19.22.

15 EXAMPLE 2 Preparation of N-(3-fluorophenyl)-N'-[5[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.



20

Step 1 Preparation of 5-[(4-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method A and making non-critical variations but starting with 3-picolyl chloride HCl and 2-amino-5-mercapto-1,3,4-thiadiazole, the title compound is obtained as a solid. mp 152-3 °C.

¹H NMR (DMSO) δ 4.30, 7.33, 7.74, 8.43, 8.48.

IR (mull) 3271, 3099, 2499, 2319, 2279, 2202, 2068, 1641, 1510, 1480, 1432, 1416, 1138, 1028, 712, cm⁻¹.

Anal. Calcd for C₈H₈N₄S₂: C, 42.84; H, 3.60; N, 24.98; S, 28.59.

30 Found: C, 42.43; H, 3.64; N, 24.75.

Step 2 Preparation of N-(3-fluorophenyl)-N'-[5[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 2 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid. mp 173-175 °C.

^1H NMR (CH_3OH) δ 4.49, 6.78-6.84, 7.14-7.17, 7.28-7.35, 7.43-7.47, 7.95-7.98, 8.45, 8.58.

^{13}C NMR (DMSO) δ 34.5, 105.3, 105.7, 109.2, 109.5, 130.4, 130.5, 133.1, 136.7, 148.3, 149.6, 160.6, 163.8.


5 IR (mull) 3374, 1957, 1928, 1711, 1618, 1608, 1597, 1553, 1548, 1485, 1439, 1401, 1277, 1227, 1215, cm^{-1} .

Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{FN}_5\text{OS}_2$: C, 49.85; H, 3.35.

Found: C, 49.69; H, 3.47; N, 19.25.

10 **EXAMPLE 3** Preparation of N-(3-fluorophenyl)-N'-[5[(4-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.

15



Step 1 Preparation of 5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method A and making non-critical variations but starting with 4-picolyl chloride HCl and 2-amino-5-mercapto-1,3,4-thiadiazole, the title compound is obtained as a solid. mp 183-4 °C.

^1H NMR (DMSO) δ 4.28, 7.31, 7.48.

IR (mull) 3310, 3110, 2499, 2362, 2150, 2044, 1944, 1638, 1606, 1527, 1514, 1415, 1070, 1049, 1024, cm^{-1} .

25 Anal. Calcd for $\text{C}_8\text{H}_8\text{N}_4\text{S}_2$: C, 42.84; H, 3.60; N, 24.98.

Found: C, 42.80; H, 3.74; N, 24.77.

Step 2 Preparation of N-(3-fluorophenyl)-N'-[5[(4-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 3 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid. mp 178-179 °C.

^1H NMR (DMSO) δ 4.46, 6.82-6.91, 7.18, 7.28-7.33, 7.39-7.45, 8.50-8.52.

^{13}C NMR (DMSO) δ 36.0, 105.4, 105.7, 109.3, 109.5, 114.6, 123.8, 130.4, 130.5, 140.0, 140.1, 146.3, 149.5, 160.6, 163.8.


35 IR (mull) 3384, 3369, 1944, 1726, 1618, 1601, 1557, 1495, 1430, 1408, 1317, 1305,

1219, 1205, 1152, cm^{-1} .Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{FN}_5\text{OS}_2$: C, 49.85; H, 3.35; N, 19.38.

Found: C, 49.69; H, 3.41; N, 19.21.

- 5 **EXAMPLE 4** Preparation of N-(3-chlorophenyl)-N'-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.


10



- Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 2 and 3-chlorophenyl isocyanate, the title compound is obtained as a solid. mp 192-193 °C.
- 15 ^1H NMR (DMSO) δ 4.46, 7.07-7.09, 7.31-7.37, 7.66, 7.79-7.82, 8.45, 8.55, 9.25, 11.12.
- ^{13}C NMR (DMSO) δ 34.6, 116.7, 117.3, 117.6, 118.2, 121.6, 123.5, 130.3, 133.1, 136.4, 140.9, 148.5, 149.8, 152.1.
- IR (mull) 1987, 1917, 1709, 1608, 1600, 1577, 1562, 1490, 1408, 1401, 1300, 1246,
- 20 1225, 1211, 1059, cm^{-1} .
- Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{ClN}_5\text{OS}_2$: C, 47.68; H, 3.20; N, 18.53.
- Found: C, 47.40; H, 3.29; N, 18.29.

- EXAMPLE 5** Preparation of N-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-(trifluoromethyl)phenyl)urea
- 25

30



- Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 2 and α,α,α -trifluoro-*m*-tolyl isocyanate, the title compound is obtained as a solid.
- 35

mp 177-179 °C.

¹H NMR (DMSO) δ 4.47, 7.33-7.36, 7.53, 7.65, 7.81, 7.96, 8.45, 8.56, 9.52, 11.56.

¹³C NMR (DMSO) δ 34.6, 114.7, 114.8, 119.2, 119.5, 122.5, 123.5, 125.8, 129.3, 129.7, 130.0, 133.0, 136.5, 129.3, 148.5, 149.7.


- 5 IR (mull) 3374, 2237, 1991, 1952, 1715, 1598, 1559, 1443, 1402, 1344, 1321, 1206, 1179, 1171, 1119.

Anal. Calcd for C₁₆H₁₂F₃N₅OS₂: C, 46.71; H, 2.94; N, 17.02.

Found: C, 46.34; H, 3.08; N, 16.71.

- 10 **EXAMPLE 6** Preparation of N-(2-phenylethyl)-N'-[5-[(2-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.

15



Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 2 and phenethyl isocyanate, the title compound is obtained as a solid. mp 146-148 °C.

¹H NMR (DMSO) δ 2.73, 3.34, 4.42, 6.61, 7.19-7.36, 7.76-7.79, 8.44, 8.53, 10.91.

¹³C NMR (DMSO) δ 34.7, 35.3, 40.9, 123.5, 126.1, 128.3, 128.6, 133.1, 136.4, 138.9, 148.5, 149.8, 153.2, 161.2.

IR (mull) 3410, 3027, 2813, 1987, 1955, 1918, 1699, 1593, 1532, 1408, 1315, 1248,


- 25 752, 718, 706, cm⁻¹.

Anal. Calcd for C₁₇H₁₇N₅OS₂: C, 54.97; H, 4.61; N, 18.85.

Found: C, 54.43; H, 4.52; N, 18.76.

- 30 **EXAMPLE 7** Preparation of N-(3-fluorophenyl)-N'-[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.

35



Step 1 Preparation of 5-amino-2[2-quinolinylmethyl]thio-1,3,4-thiadiazole.

Following the general procedure outlined in Method A and making non-critical variations, the title compound is prepared from 2-chloromethylquinoline HCl and 2-amino-5-mercapto-1,3,4-thiadiazole as a solid. mp 177-8 °C.

¹H NMR (DMSO) δ 4.56, 7.26, 7.60, 7.73, 7.95, 8.32.

IR (mull) 3258, 3070, 3059, 2328, 2164, 2071, 1969, 1955, 1657, 1508, 1501, 1396, 1131, 834, 763, cm⁻¹.

Step 2 Preparation of N-(3-fluorophenyl)-N'-[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 7 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid. mp 212-214 °C.

¹H NMR (DMSO) δ 4.74, 6.84-6.87, 7.17-7.19, 7.31-7.33, 7.41-7.44, 7.58, 7.64, 7.74, 8.35.


¹³C NMR (DMSO) δ 105.4, 105.7, 109.5, 114.6, 121.1, 126.5, 126.7, 127.8, 128.3, 129.8, 130.4, 130.5, 136.9, 146.9, 156.9, 160.6, 163.8.

IR (mull) 3373, 1945, 1930, 1716, 1614, 1599, 1561, 1497, 1426, 1409, 1313, 1301, 1216, 1204, 778, cm⁻¹.

Anal. Calcd for C₁₉H₁₄FN₅O₂: C, 56.19; H, 4.24; N, 16.38.

Found: C, 55.25; H, 3.59; N, 16.63.

EXAMPLE 8 Preparation of 1,1-Dimethylethyl 3-[[[5-[[[3-fluorophenyl)amino]-carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate.



Step 1 Preparation of 1,1-dimethylethyl 3-[[[5-amino-1,3,4-thiadiazole-2-yl]methyl]benzoate.

A solution of 3-(chloromethyl)benzoyl chloride (5.3 mmol, 0.75 ml) in THF (10 ml) at 0 °C. *t*-BuOK (5.8 mmol, 5.8 ml) is added. After three hours, the reaction is

quenched with H₂O and diluted with EtOAc. The aqueous phase is extracted with EtOAc (2x), and the combined organics are washed with brine. After drying over MgSO₄, the solvent is removed *in vacuo*. The resulting oil is dissolved in CH₃CN (15 ml). 5-Amino-1,3,4-thiadiazole-2-thiol (5.3 mmol, 0.71 g) and triethylamine (5.8 mmol, 0.81 ml) are added to the reaction, which is stirred overnight. The solvent is removed *in vacuo*, and the title compound is recrystallized from CH₃OH as a solid. mp 163-165 °C.

¹H NMR (DMSO) δ 1.52, 4.34, 7.29, 7.42, 7.55, 7.77, 7.85.

¹³C NMR (DMSO) δ 27.7, 37.8, 80.7, 127.9, 128.6, 129.3, 131.4, 133.3, 137.8, 148.8, 164.6, 169.9.

IR (mull) 3298, 3107, 2398, 2334, 1982, 1921, 1710, 1504, 1310, 1292, 1167, 1110, 1077, 765, 699, cm⁻¹.

Step 2 Preparation of 1,1-Dimethylethyl-3-[[[5-[[[(3-fluorophenyl)amino]-carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 8 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid. mp 177-178 °C. ¹H NMR (DMSO) δ 1.51, 4.50, 6.82-6.89, 7.16-7.19, 7.28-7.33, 7.41-7.46, 7.62, 7.78, 7.89.


¹³C NMR (DMSO) δ 27.6, 37.1, 80.7, 105.3, 105.7, 109.2, 109.5, 114.6, 128.0, 128.7, 129.3, 130.3, 130.7, 131.4, 133.3, 137.6, 160.6, 136.8, 164.5.

IR (mull) 3373, 2422, 1947, 1905, 1712, 1612, 1605, 1546, 1442, 1414, 1307, 1299, 1278, 1219, 1207, cm⁻¹.

Anal. Calcd for C₂₁H₂₁FN₄O₃S₂: C, 54.77; H, 4.60; N, 12.16.

Found: C, 54.96; H, 4.50; N, 12.05.

EXAMPLE 9 Preparation of N-(3-Fluorophenyl)-N'-[5-[[[5-phenyl-3-pyridinyl)methyl]thio]-1,3,4-thiadiazole-2-yl]urea.



Step 1 Preparation of 5-Bromo-3-pyridine methanol.

Triethylamine (78 mmol, 10.8 ml) is added to a slurry of 5-bromonicotinic

acid (74 mmol, 15.0 g) in toluene (400 ml), and all solids are dissolved. Ethyl chloroformate (78 mmol, 7.4 ml) is added, and the reaction is stirred at room temperature for one hour. The salts are removed by filtration, and the solvent is removed *in vacuo*, yielding yellow oil. The oil is dissolved in THF (200 ml) and this solution is added dropwise to a slurry of LAH (78 mmol, 2.93 g) in THF (100 ml) cooled to -78 °C. The reaction is stirred at -78 °C for one hour, and then quenched sequentially with 3 ml H₂O, 3 ml 15% NaOH, and 9 ml H₂O. The resulting salts are removed by filtration and are rinsed with EtOAc. The filtrate is dried over MgSO₄ and concentrated to orange oil. The title compound is obtained as an oil and purified by flash chromatography (5% CH₃OH/CH₂Cl₂).

¹H NMR (CDCl₃) δ 2.74, 4.72, 7.89, 8.45, 8.55.

Step 2 Preparation of 5-bromo-3-pyridine methanol tetrahydropyran ether.

The product of Step 1, Example 9 is dissolved in CH₂Cl₂ (250 ml) and cooled to 0 °C. Dihydropyran (182 mmol, 16 ml) and pTsOH (0.1 g) is added. The reaction is heated to reflux for 5 hours. After cooling to room temperature, the reaction is diluted with EtOAc (500 ml) and an aqueous solution (100 ml brine, 100 ml sat. NaHCO₃, and 100 ml H₂O). The organic phase is washed with sat. NaHCO₃ and brine. It is dried over MgSO₄ and concentrated to give the title compound as orange oil. The product is purified by flash chromatography (2% CH₃OH/CH₂Cl₂).

¹H NMR (CDCl₃) δ 1.57-1.85, 3.53-3.57, 3.82-3.88, 4.48, 4.70, 4.77, 7.85, 8.49, 8.58.

Step 3 Preparation of 5-Phenyl-3-pyridinemethanol.

To a slurry of the product of Step 2, Example 9 (6.0 mmol, 1.67 g) and Pd(PPh₃)₂Cl₂ (0.03 mmol, 0.02 g) in toluene (12 ml) is added 6 ml 2M aq. Na₂CO₃. Next, phenyl boronic acid (7.2 mmol, 0.93 g) in CH₃OH (4 ml) is added. The reaction is heated to 70 °C for 3 hours. After cooling to room temperature, the reaction is diluted with CH₂Cl₂ and 2 M Na₂CO₃. The layers are separated, and the organic phase is dried over MgSO₄. After filtering through silica gel to remove metal salts, the solvent is removed *in vacuo* leaving a yellow oil. It is dissolved in CH₃OH (20 ml), and pTsOH (0.1 g) is added. The reaction is stirred overnight at room temperature, and then overnight at 60 °C. The solvent is removed *in vacuo*, the residual oil is dissolved in CHCl₃. The organic solution is washed with NaHCO₃ and brine, and dried over MgSO₄. It is concentrated to give the title compound as oil. The product is isolated by flash chromatography (60%EtOAc/hex). which crystallized on standing. mp 65-67 °C.

¹H NMR (CDCl₃) δ 4.71, 5.98, 7.25-7.42, 7.87, 8.41, 8.50.


¹³C NMR (DMSO) δ 62.1, 127.0, 128.3, 128.4, 129.1, 134.2, 134.3, 136.7, 136.9,

145.5.

Step 4 Preparation of N-(3-Fluorophenyl)-N'-[5-[[5-phenyl-3-pyridinyl)methyl]thio]-1,3,4-thiadiazole-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 3, Example 9 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid.

EXAMPLE 10 Preparation of N-(3-Fluorophenyl)-N'-[5-[[[5-(3-thienyl)-3-pyridinyl)methyl]thio]1,3,4-thiadiazol-2-yl]urea.



15

Step 1 Preparation of 5-(3-thienyl)-3-pyridine methanol.

Following the general procedure outlined in Steps 1-3, Example 9 and making non-critical variations but starting with the product of step 2, Example 9 and 3-thiophene boronic acid, the title compound is obtained as a solid. The product is purified by flash chromatography (60% EtOAc/hex), which crystallized on standing.

^{13}C NMR (CD_3OD) δ 62.5, 123.2, 126.8, 128.3, 130.0, 133.2, 134.1, 139.3, 146.5, 147.1

Step 2 Preparation of 5-[[[5-(3-thienyl)-3-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method A and making non-critical variations but starting with the product of Step 1, Example 10, the title compound is obtained as a solid. The product is recrystallized from $\text{CH}_3\text{OH}/\text{EtOAc}$. mp 183-185 °C.

^1H NMR (DMSO) δ 4.33, 7.35, 7.57-7.59, 7.68-7.71, 7.98-7.99, 8.05, 8.40, 8.84.

^{13}C NMR (DMSO) δ 35.4, 122.3, 125.8, 127.7, 130.3, 133.3, 133.5, 137.7, 146.0, 148.2, 148.4, 170.1.

Step 3 Preparation of N-(3-fluorophenyl)-N'-[5-[[[5-(3-thienyl)-3-pyridinyl)methyl]thio]1,3,4-thiadiazol-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 2, Example 10 and 3-

fluorophenyl isocyanate, the title compound is obtained as a solid. The product is recrystallized from CH₃OH. mp 221-223 °C.

¹H NMR (DMSO) δ 4.50, 6.84-6.87, 7.17-7.20, 7.28-7.33, 7.41-7.45, 7.58-7.60, 7.68-7.71, 8.00-8.01, 8.11-8.13, 8.47, 8.85.

5 ¹³C NMR (DMSO) δ 34.6, 105.2, 105.7, 109.2, 109.5, 114.6, 122.4, 125.8, 127.7, 130.3, 133.0, 133.6, 137.6, 146.1, 148.2, 160.6, 163.8.


IR (mull) 3375, 1726, 1601, 1560, 1495, 1432, 1401, 1316, 1206, 1173, 848, 783, 735, 653, 644, cm⁻¹.

Anal. Calcd for C₁₉H₁₄FN₅OS₃: C, 51.45; H, 3.18; N, 15.79.

10 Found: C, 51.39; H, 3.34; N, 15.48.

EXAMPLE 11 Preparation of N-[3-fluorophenyl]-N'-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]urea.

15



Step 1 Preparation of 5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-amine.

20 Following the general procedure outlined in Method B and making non-critical variations but starting with 1-phenylpropyl alcohol and 2-amino-5-mercapto-1,3,4-thiadiazole, the title compound is obtained as a solid. The crude product is purified by flash chromatography (5% CH₃OH/CH₂Cl₂). mp 113-114 °C.

¹H NMR (CDCl₃) δ 0.94, 1.97-2.15, 4.40, 5.30, 7.25-7.31.

25 ¹³C NMR (DMSO) δ 11.8, 28.5, 54.9, 127.5, 127.7, 128.4, 140.5, 148.0, 170.4.

Step 2 Preparation of N-[3-Fluorophenyl]-N'-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 11 and 3-

30 fluorophenyl isocyanate, the title compound is obtained as a solid. The crude product is recrystallized from CH₃OH/EtOAc. mp 165-167 °C.

¹H NMR (DMSO) δ 0.85, 1.92-2.07, 4.56, 6.82-6.87, 7.16-7.44, 9.25, 11.15.


¹³C NMR (DMSO) δ 11.8, 28.8, 54.5, 105.3, 105.7, 114.6, 127.6, 127.7, 128.5, 130.4, 130.5, 140.1, 140.3, 160.6, 163.8, 170.9, 183.9, 223.3.

35 IR (mull) 1952, 1917, 1710, 1607, 1551, 1493, 1438, 1411, 1309, 1295, 1280, 1206, 722, 699, 678, cm⁻¹.

Anal. Calcd for $C_{18}H_{17}FN_4OS_2$: C, 55.65; H, 4.41; N, 14.42.

Found: C, 55.55; H, 4.51; N, 14.21.

EXAMPLE 12 Preparation of N-[5-[(cyclopropylphenylmethyl)thio]-1,3,4-thiadiazole-2-yl]urea.



Step 1 Preparation of 5-[(cyclopropylphenylmethyl)thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method D and making non-critical variations but starting with α -cyclopropyl benzyl alcohol and 2-amino-5-mercapto-1,3,4-thiadiazole, the title compound is obtained as a solid. mp 148-150 °C.

1H NMR (DMSO) δ 2.51-2.57, 3.19, 6.22-6.31, 6.45, 7.19-7.38.

^{13}C NMR (DMSO) δ 33.46, 33.8, 125.8, 127.1, 127.7, 128.2, 128.5, 131.2, 136.8, 149.9, 169.4.

Step 2 Preparation of Preparation of N-[5-[(cyclopropylphenylmethyl)thio]-1,3,4-thiadiazole-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 12 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid. The crude product is isolated by flash chromatography (5% CH_3OH/CH_2Cl_2) and recrystallized from CH_3OH . mp 186-187 °C.

1H NMR (DMSO) δ 2.60, 3.34-3.36, 6.23-6.33, 6.47, 6.83-7.03, 7.19-7.22, 7.26-7.38, 7.45, 9.24, 11.11.

^{13}C NMR (DMSO) δ 32.4, 33.1, 105.3, 105.7, 109.2, 109.5, 114.6, 125.9, 127.2, 127.7, 128.5, 130.4, 130.5, 131.3, 136.7, 160.6, 136.8, 184.2.

IR (mull) 3381, 1996, 1950, 1721, 1608, 1558, 1497, 1445, 1406, 1326, 1315, 1281, 1222, 1210, 737, cm^{-1} .


Anal. Calcd for $C_{19}H_{17}FN_4OS_2$: C, 56.98; H, 4.28; N, 13.99.

Found: C, 56.92; H, 4.25; N, 13.94.

EXAMPLE 13

Preparation of N-(3-fluorophenyl)-N'-[5-[[1-(phenylmethyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea

5



Step 1 Preparation of 5-[[1-(phenylmethyl)propyl]thio]-1,3,4-thiadiazole-2-amine.

10

Following the general procedure outlined in Method D and making non-critical variations but starting with 1-phenyl-2-butanol and 2-amino-5-mercapto-1,3,4-thiadiazole, the title compound is obtained as a solid. The crude product is isolated by flash chromatography (5% CH₃OH/CH₂Cl₂), which is slowly crystallized.

15

¹H NMR (CD₃OD) δ 1.03, 1.51-1.75, 2.88-2.98, 3.47-3.52, 7.18-7.28, 7.95.

¹³C NMR (CD₃OD) δ 26.2, 30.6, 35.7, 53.0, 126.3, 128.1, 129.1, 138.6, 148.1, 162.2, 170.1.

Step 2 Preparation of N-(3-fluorophenyl)-N'-[5-[[1-(phenylmethyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea.

20

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 1, Example 13 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid. The crude product is recrystallized from EtOAc. mp 128-130 °C.

¹H NMR (DMSO) δ 0.99, 1.51-1.73, 2.95, 3.68-3.73, 6.83-6.90, 7.18-7.37, 7.45, 9.30, 11.12.

¹³C NMR (DMSO) δ 10.9, 26.3, 52.8, 105.3, 105.7, 109.2, 109.5, 114.6, 114.6, 126.4, 128.2, 129.1, 130.4, 130.5, 128.5, 160.6, 163.8.

IR (mull) 3377, 2418, 2242, 1958, 1725, 1616, 1587, 1544, 1487, 1428, 1311, 1277, 1209, 861, 709, cm⁻¹.

30


Anal. Calcd for C₁₉H₁₉FN₄OS₂: C, 56.70; H, 4.76; N, 13.92.

Found: C, 56.78; H, 4.78; N, 13.86.

EXAMPLE 14

Preparation of N-(3-Fluorophenyl)-N'-[5-[[1-phenylbutyl]thio]-1,3,4-thiadiazol-2-yl]urea.

35



5

Step 1 Preparation of 5-[(1-phenylbutyl)thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method D and making non-critical variations but starting with 1-phenyl-1-butanol and 2-amino-5-mercapto-1,3,4-thiadiazole, the title compound is obtained as a solid. The crude product is purified by flash chromatography (5% CH₃OH/CH₂Cl₂). mp 108-110 °C.

¹H NMR (DMSO) δ 0.82, 1.16-1.30, 1.85-1.93, 4.41, 7.22-7.31.

¹³C NMR (DMSO) δ 13.3, 20.0, 37.4, 53.1, 127.4, 127.7, 128.4, 140.7, 148.0, 170.4.

Step 2 Preparation of N-(3-Fluorophenyl)-N'-[5-[(1-phenylbutyl)thio]-1,3,4-thiadiazol-2-yl]urea.

Following the general procedure outlined in Method D and making non-critical variations but starting with the product of Step 1, Example 14 and 3-fluorophenyl isocyanate, the title compound is obtained as a solid. The crude product is recrystallized from EtOAc/hex. mp 166-168 °C.

¹H NMR (DMSO) δ 0.84, 1.15-1.28, 1.93-1.98, 4.63, 6.83-6.88, 7.18-7.44.

¹³C NMR (DMSO) δ 13.3, 20.1, 37.6, 52.7, 105.3, 105.7, 109.2, 109.5, 114.6, 127.6, 127.0, 128.5, 130.4, 130.5, 140.6, 160.6, 163.8.


IR (mull) 2315, 1954, 1912, 1712, 1620, 1610, 1563, 1495, 1440, 1414, 1309, 1298, 1280, 1209, 698, cm⁻¹.

Anal. Calcd for C₁₉H₁₉FN₄OS₂: C, 56.70; H, 4.76; N, 13.92.

Found: C, 56.87; H, 4.85; N, 13.86.

EXAMPLE 15 Preparation of N-(3-fluorophenyl)-N'-[5[[1-(2-pyridinyl)propyl]thio]-1,3,4-thiadiazole-2-yl]urea.

30



Step 1 Preparation of α-Ethyl-2-pyridinemethanol.

2-Pyridinecarboxaldehyde (40 mmol, 3.8 ml) is dissolved in THF (200 ml) and

cooled to 0 °C. Ethyl magnesium bromide (48 mmol, 48 ml) is added via addition funnel over 20 minutes. The reaction is stirred for 3.5 hours at 0 °C, and then quenched with H₂O. It is diluted Et₂O, and the layers are separated. The aqueous phase is extracted with Et₂O (2x), and the combined ethereal layers are washed with 5 brim and dried over MgSO₄. It is concentrated to provide the title compound as oil. ¹H NMR (CDCl₃) δ 0.94, 1.67-1.92, 4.69, 7.16-7.23, 7.64-7.70, 8.53-8.56.


Step 2 Preparation of 5-[[1-(2-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method C and making non-critical variations but starting with the product of Step 1, Example 15, the title 10 compound is obtained. The crude product is purified by flash chromatography (5% CH₃OH/CH₂Cl₂), which crystallized on standing. The pale brown solid was treated with decolorizing carbon and recrystallized from CH₃OH/EtOAc. mp 110-112 °C. ¹H NMR (DMSO) δ 0.83, 1.94-2.10, 4.46, 7.24-7.38, 7.71-7.77, 8.50-8.52. ¹³C NMR (DMSO) δ 11.6, 27.6, 56.1, 122.5, 122.7, 136.7, 148.1, 149.1, 159.2, 170.4.

15 Step 3 Preparation of N-(3-fluorophenyl)-N'-[5[[1-(2-pyridinyl)propyl]thio]-1,3,4-thiadiazole-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 2, Example 15 and 3-fluorophenyl isocyanate, the title compound is obtained. The crude product is 20 recrystallized (2x) from EtOAc as solid. mp 173-175 °C. ¹H NMR (DMSO) δ 0.85, 2.04-2.11, 4.70, 6.83-6.88, 7.18, 7.26-7.26, 7.41-7.44, 7.73-7.79, 8.52, 9.25, 11.10. ¹³C NMR (DMSO) δ 11.5, 28.0, 55.6, 105.3, 105.7, 109.2, 109.5, 114.6, 122.7, 122.7, 130.4, 130.5, 136.8, 149.2, 158.9, 160.6, 163.8. IR (mull) 2413, 2016, 1980, 1903, 1705, 1615, 1559, 1545, 1485, 1438, 1405, 1298, 1277, 1207, 1199, cm⁻¹. Anal. Calcd for C₁₇H₁₆FN₅OS₂: C, 52.43; H, 4.14; N, 17.98. Found: C, 52.51; H, 4.10; N, 17.72.

30 EXAMPLE 16 Preparation of N-(3-fluorophenyl)-N'-[5[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazole-2-yl]urea.



35

Step 1 Preparation of α -Ethyl-3-pyridinemethanol.

Following the procedure outlined in Steps 1, Example 15 and making non-critical variations but starting with 3-pyridinecarboxaldehyde, the title compound is obtained. The crude product is purified by flash chromatography.

- 5 ^1H NMR (CDCl_3) δ 0.94, 1.72-1.90, 2.17, 4.66, 7.28-7.30, 7.68-7.72, 8.51, 8.55.

Step 2 Preparation of 5-[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method A and making non-critical variations but starting with the product of Step 1, Example 16, the title compound is obtained. The crude product is purified by flash chromatography (5%

- 10 $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$).

^1H NMR (DMSO) δ 0.18, 1.21-1.34, 3.62, 6.57-6.61, 7.01-7.04, 7.56-7.61.

^{13}C NMR (DMSO) δ 11.8, 27.9, 52.2, 123.5, 135.0, 136.5, 147.1, 148.6, 149.1, 170.5

Step 3 Preparation of N-(3-fluorophenyl)-N'-[5[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazole-2-yl]urea.

- 15 Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 2, Example 16 and 3-fluorophenyl isocyanate, the title compound is obtained. The crude product is purified by flash chromatography (5% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$), which crystallized on standing. The solid is recrystallized from EtOAc/hex. mp 157-159 $^\circ\text{C}$.

- 20 ^1H NMR (DMSO) δ 0.89, 1.97-2.09, 4.63, 6.83-6.88, 7.17, 7.28-7.44, 7.78-7.81, 8.44, 8.52, 9.28, 11.22.

^{13}C NMR (DMSO) δ 11.8, 28.1, 51.8, 105.4, 105.7109, 3, 109.5, 114.6, 123.6, 130.4, 130.5, 135.0, 136.3, 140.0, 140.1, 148.7, 149.1, 160.6, 163.7.

IR (mull) 1956, 1924, 1707, 1616, 1591, 1548, 1488, 1433, 1424, 1302, 1281, 1218,


- 25 1199, 806, 770, cm^{-1} .

Anal. Calcd for $\text{C}_{17}\text{H}_{16}\text{FN}_5\text{OS}_2$: C, 52.43; H, 4.14; N, 17.98.

Found: C, 52.60; H, 4.31; N, 17.81.

EXAMPLE 17 Preparation of N-(3-fluorophenyl)-N'-[5[[1-(4-pyridinyl)propyl]thio]-1,3,4-thiadiazole-2-yl]urea.

30



35

Step 1 Preparation of α -Ethyl-4-pyridinemethanol.

Following the procedure outlined in Steps 1, Example 15 and making non-critical variations but starting with 4-pyridinecarboxaldehyde, the title compound is obtained. The crude product is purified by flash chromatography (50% EtOAc/hex to EtOAc).

^1H NMR (CDCl_3) δ 0.97, 1.72-1.82, 4.64, 4.75, 7.27-7.30, 8.52-8.55.

Step 2 Preparation of 5-[[1-(4-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-amine.

Following the general procedure outlined in Method C and making non-critical variations but starting with the product of Step 2, Example 17 and 3-fluorophenyl isocyanate, the title compound is obtained. The crude product is purified by flash chromatography (5% $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$).

Step 3 Preparation of N-(3-fluorophenyl)-N'-[5[[1-(4-pyridinyl)propyl]thio]-1,3,4-thiadiazole-2-yl]urea.

Following the general procedure outlined in Method E and making non-critical variations but starting with the product of Step 2, Example 17 and 3-fluorophenyl isocyanate, the title compound is obtained. The crude product is crystallized from EtOAc as a solid. mp 168-170 °C.

^1H NMR (DMSO) δ 0.89, 1.94-2.05, 4.60, 6.83-6.89, 7.18, 7.29-7.44, 8.49-8.51, 10.35, 11.20.

^{13}C NMR (DMSO) δ 12.4, 29.56, 55.5, 107.2, 107.6, 110.9, 111.2, 124.8, 125.8, 131.3, 131.5, 150.4, 125.9, 157.7, 162.9, 166.1.

IR (mull) 1937, 1708, 1699, 1624, 1614, 1606, 1574, 1532, 1497, 1489, 1433, 1423, 1309, 1282, 1226, cm^{-1} .

Anal. Calcd for $\text{C}_{17}\text{H}_{16}\text{FN}_5\text{OS}_2$: C, 52.43; H, 4.14; N, 17.98.

Found: C, 52.10; H, 4.07; N, 18.16.

INHIBITION OF β_2 INTEGRIN LIGAND BINDING ASSAYS

The compounds may be tested in one of several biological assays to determine the concentration of compound which is required to have a given pharmacological effect.

To identify inhibitors of β_2 integrin ligand binding function, two primary and two secondary assays are performed. The assays are established to identify compounds which inhibit the interaction of either LFA-1 or Mac-1 with immobilized ICAM-1. The interaction of the β_2 integrins with ICAM-1 plays an important role in a number of adhesive events during normal immune and inflammatory responses including antigen presentation to T cells, T cell mediated cytotoxicity, and the firm

attachment and extravasation of circulating leukocytes into the surrounding tissue. Both the primary LFA-1 and Mac-1 adhesion assays are performed using the well-known scintillation proximity assay (SPA) bead technology which is discussed in further in Cook, N.D. et. al. *Pharmaceutical Manufacturing International* (1992) pp. 49-53, "SPA: A revolutionary new technique for drug screening". Bosworth, N. and Towers, P. *Nature* (1989) 341:167-168, "Scintillation proximity assay". Undefriend, S., Gerber, L. and Nelson, N. *Analytical Biochemistry* (1987) 161: 494-500 "Scintillation Proximity Assay, a sensitive and continuous isotopic method for monitoring ligand-receptor and antigen-antibody interactions".

10 Briefly, the assay relies upon three major components: a radiolabeled CHO cell that has been transfected with the heterodimeric either LFA-1 or Mac-1 molecule and is functionally expressed on the cell surface; a secreted soluble form of intercellular adhesion molecule produced from a transfected CHO cell line and which has subsequently been biotinylated; and streptavidin SPA beads to monitor the
15 interaction of these two components. The SPA technology is utilized because it obviates the need for a wash step(s), allowing low affinity interactions to remain undisturbed.

Stable CHO cells expressing either LFA-1 or Mac-1 were established. Cells were grown in modified Dulbecco's media and labeled overnight in a leucine
20 deficient media in the presence of ^3H -leucine (10 mCi/ 10^6 cells for LFA-1 and 50 mCi/ 10^6 cells for Mac-1). After labeling, cells (1×10^4 LFA-1 and 5×10^4 for Mac-1) were activated with phorbol ester (100 nM for LFA-1 and 500 nM for Mac-1) and allowed to react with streptavidin SPA beads previously coated with biotinylated soluble ICAM-1 dispensed into 96 well plates. To inhibit adhesion to ICAM-1 coated
25 SPA beads, 4X stock of compound, blocking antibodies or buffer control were added to the wells immediately prior to the addition of cells. Following incubation for 8 hours, adhesion was quantitated in the wells using a scintillation counter.

For further analysis of compounds that inhibit LFA-1 interactions, a secondary adhesion assay using JY and human soluble ICAM-1 was established. JY
30 cells, a human lymphoblastoid cell line, constitutively expresses LFA-1. Microtiter wells were coated with soluble ICAM-1 diluted in 0.1 M NaCO_3 buffer (pH 8.0) overnight at 4°C . The remaining binding sites on the plastic were blocked with phosphate buffered saline (PBS) containing 1 mM $\text{Ca}^{2+}/\text{Mg}^{2+}$ and 1% human serum albumin (PBS/HSA) for 1 hour at 37°C . JY cells were harvested by centrifugation
35 and fluorescently labeled with 2'7'-bis-(carboxyethyl)-5(6)-carboxy-fluorescein. JY cells were then washed once in PBS/HSA, and stimulated with phorbol 12-myristate

13-acetate (PMA; 50 ng/ml) for 5 minutes. The microtiter plates was washed once with PBS containing 1 mM $\text{Ca}^{2+}/\text{Mg}^{2+}$ and 0.5% Tween-20 and then immediately washed with PBS/HSA. A 80 mL aliquot of cells (1×10^6) was plated in triplicate on the microtiter wells. To inhibit adhesion to ICAM-1 coated wells, a 20 ml aliquot of 5X stock of compound, blocking antibodies or buffer control were added to the wells immediately prior to the addition of cells to the wells. Following incubation for 30 minutes at 37°C, the plates were washed with PBS/HSA. Fluorescence was quantitated in the wells using a Pandex fluorescence concentration analyzer.

For further analysis of compounds that inhibit Mac-1 interactions, a secondary adhesion assay using human neutrophils and human soluble ICAM-1 was established. Human neutrophils were used because of the limited availability of cultured cell lines expressing Mac-1. Mac-1 expressed on stimulated neutrophils play a major role in the adherence of neutrophils to endothelial cells and transendothelial migration via its interaction with ICAM-1. Microtiter wells were coated with soluble ICAM-1 diluted in 0.1 mM NaCO_3 buffer (pH 8.0) overnight at 4°C. The remaining binding sites on the plastic were blocked with PBS containing 1 mM $\text{Ca}^{2+}/\text{Mg}^{2+}$ and 1% fetal calf serum (PBS/FCS) at room temperature for 30 minutes. Neutrophils were purified from the peripheral blood of healthy adult individuals by dextran sedimentation and centrifugation on a Ficoll-Hypaque solution. Neutrophils were then fluorescently labeled with 2'7'-bis-(carboxyethyl)-5(6)-carboxy-fluorescein. The cells were then washed in PBS/FCS and subjected to hypotonic lysis. To each well, 30 ml of PBS/FCS, 10 ml 10X stock of compound or blocking antibody, 10 ml f-Met-Leu-Phe (10^{-7}M), and 50 ml of cells (2×10^6 cells/ml) was plated in triplicate. Following incubation for 30 minutes at 37°C, the plates were washed with PBS. Fluorescence was quantitated in the wells using a Pandex fluorescence concentration analyzer.

The inhibition results are given in Table 1. LFA/SPA and Mac-1/SPA refer to LFA-1 and Mac-1 adhesion assays are performed using the SPA technology; JY/ICAM refers to a secondary adhesion assay, inhibition of LFA-1 interactions, using JY and human soluble ICAM-1. PMN/ICAM refers to a secondary adhesion assay, inhibition of Mac-1 interactions, using human neutrophils and human soluble ICAM-1.


TABLE 1

Compound No.	LFA-1	Mac-1	PMN/ICAM	JY/ICAM
1	<25	<25	>10.	12
2	0.52	3.2	13.0	>20
3	0.74	<1	>10	>20
4	1.1	1.5	0.6	8.0
5	0.21	1.3	8.0	13.0
6	11.6	18.8	10	>20
7	0.45	0.83	15	14
8	0.3	0.51	5.0	7.0
9	0.7	1.2	2.0	12
10	0.7	0.6	2.0	10.0
11	0.3	0.1	0.8	5.0
12	>25	>25	0.8	8.0
13	0.4	0.5	-	-
14	0.3	0.6	0.8	<0.5
15	1.2	1.2	5.0	6.0
16	1.6	1.6	0.7	7.0
17	1.9	2	5.0	6.0

We claim:

1. A compound of a formula I

5




I

or pharmaceutically acceptable salts thereof wherein:

10 R_1 is

- a) -aryl,
- b) -aryl wherein aryl is substituted with one to three R_4 ,
- c) -Q,
- d) -Q wherein Q is substituted with one to three R_4 ,
- 15 e) -Het,
- f) -Het wherein Het is substituted with one to three R_4 ,

20



- h) , optionally substituted with C_{1-4} alkyl or C_{3-6} cycloalkyl,
- i) C_{1-6} carboalkoxy,
- 25 j) $-C(=O)-CH_2CO_2(C_{1-4} \text{ alkyl})$,
- k) $-C(=O)NH(CH_2)_fR_5$,
- l) C_{1-10} alkyl,
- m) C_{1-10} alkyl substituted with one to three R_6 ,
- 30 n) C_{1-10} alkenyl, or
- o) C_{1-10} alkenyl substituted with one to three R_6 ;

 R_2 is

- a) $-(CH_2)_j(CR_7R_8)_k-$;

 R_3 is

35

- a) $-(CR_9R_{10})_l(CH_2)_j$ -aryl,
- b) $-(CR_9R_{10})_l(CH_2)_j$ -aryl wherein aryl is substituted with one to

three R_{11} ,

- c) $-(CR_9R_{10})_l(CH_2)_f-Q$,
- d) $-(CR_9R_{10})_l(CH_2)_f-Q$ wherein Q is substituted with one to three R_{11} ,
- e) $-(CR_9R_{10})_l(CH_2)_f-Het$,
- 5 f) $-(CR_9R_{10})_l(CH_2)_f-Het$ wherein Het is substituted with one to three R_{11} , or
- g) $-(CR_9R_{10})_l-(CH_2)_l$ -pentafluorophenyl;

R_4 is

- a) halo,
- 10 b) C_{1-4} alkyl,
- c) C_{3-6} cycloalkyl,
- d) C_{1-4} alkoxy,
- e) aryl,
- f) Q,
- 15 g) Het,
- h) C_{1-4} carboalkoxy,
- i) C_{1-4} monoalkylamino,
- j) C_{1-4} dialkylamino,
- k) amido,
- 20 l) C_{1-4} alkylthio,
- m) trihalomethyl,
- n) $-(CH_2)_l-O-(C_{1-4} \text{ alkyl})$,
- o) nitro,
- p) mercapto,
- 25 q) nitrine,
- r) cyano,
- s) hydroxy,
- t) $-NHC(=O)(C_{1-4} \text{ alkyl})$, or
- u) $-NHSO_2(C_{1-4} \text{ alkyl})$;

30 R_5 is

- a) C_{1-8} alkyl,
- b) aryl,
- c) Q, or
- d) Het;

35 R_6 is

- a) halo,

- b) hydroxy,
- c) C₁₋₄ alkoxy,
- d) C₁₋₄ carboalkoxy,
- e) amido,
- 5 f) nitro,
- g) trihalomethyl,
- h) cyano,
- i) mercapto,
- j) C₁₋₄ alkylthio, or
- 10 k) C₁₋₈ alkyl;

R₇ and R₈ are the same and different and are

- a) H,
- b) C₁₋₆ alkyl,
- c) C₃₋₆ cycloalkyl,
- 15 d) -(CH₂)₁-O-C₁₋₄ alkyl,
- e) -(CH₂)₁-Q, or
- f) -(CH₂)₁-Het;

R₉ and R₁₀ are the same and different and are

- a) H,
- 20 b) C₁₋₄ alkyl,
- c) C₁₋₄ alkoxy,
- d) C₃₋₆ cycloalkyl, or
- e) C₁₋₄ carboalkoxy;

R₁₁ is

- 25 a) C₁₋₄ alkyl,
- b) C₁₋₄ alkoxy,
- c) trihalomethyl,
- d) halo,
- e) nitro,
- 30 f) cyano,
- g) nitrine,
- h) C₁₋₄ acyl,
- i) C₁₋₄ carboalkoxy, or
- j) carboxyl;

35 aryl is monocarbocyclic, or bicarbocyclic aromatic moiety;

Q is 5- to 10-membered saturated heterocyclic moiety having one to three atoms

selected from the group consisting of oxygen, nitrogen, and sulfur;

Het is 5- to 10-membered unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of oxygen, nitrogen, and sulfur;

j is 0, 1, 2 or 3;

5 *k* is 0, 1, 2, 3, 4, 5 or 6;

l is 0, 1, 2, 3, 4 or 5;

n is 0, 1 or 2; and with the following provisos:

a) where R_3 is a), R_1 is other than c) through f);

10 b) where R_3 is aryl substituted with cyano, R_1 is other than phenyl substituted with cyano, unsubstituted pyridyl, furyl and $-C(=O)-NHCH_2$ -pyridyl.

2. A compound of claim 1 which is

- a N-[5-[[[(3,5-Dimethoxyphenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- 15 b N-[5-[[[(4-Methoxyphenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- c N-[5-[[[(3,4-Dimethoxyphenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- d N-[5-[[[(1,3-Dihydro-1,3-dioxo-2H-isoindol-2-yl)hexyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- 20 e N-[5-[[[(1,1'-Biphenyl)-4-ylmethyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- f (E)-N-[5-[[[(3,7-Dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(2-phenylethyl)urea,
- 25 g (E)-N-[5-[[[(3,7-Dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- h (E)-N-[5-[[[(3,7-Dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(1-(2-naphthalenyl)ethyl)urea,
- i N-(2-Phenylethyl)-N'-[5-[[[(phenylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- 30 j Methyl [[5-[[[(2-phenylethyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]acetate,
- k Methyl [[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]acetate,
- l t-Butyl [[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]acetate,
- 35 m Methyl 3-[[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-

- yl]thio)methyl]benzoate,
- n Methyl 3-[[[5-[[[(2-trifluoromethylphenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio)methyl]benzoate,
- o Methyl 3-[[[5-[[[(3-trifluoromethylphenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio)methyl]benzoate,
- 5 p Methyl 3-[[[5-[[[(4-trifluoromethylphenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio)methyl]benzoate,
- q 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-octylacetamide,
- 10 r N-(3-Cyanophenyl)-N'-[5-[(2-fluoro-4-nitrophenyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- s N-[5-[(Cyanomethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- t N-(3-Cyanophenyl)-N'-[5-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 15 u N-(3-Cyanophenyl)-N'-[5-[(2-quinoliny)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- v Methyl 4-[[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-3-oxobutanoate,
- w N-(3-cyanophenyl)-N'-[5-[(3-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- x N-[5-[(5-Cyanopentyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- 20 y N-[5-[[[(4-Chloro-2-nitrophenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(3-cyanophenyl)urea,
- z N-(3-Cyanophenyl)-N'-[5-(2-propenylthio)-1,3,4-thiadiazol-2-yl]urea,
- aa N-(3-Cyanophenyl)-N'-[5-(2-propynylthio)-1,3,4-thiadiazol-2-yl]urea,
- bb N-(3-cyanophenyl)-N'-[5-(octylthio)-1,3,4-thiadiazol-2-yl]urea,
- 25 cc Methyl 3-[[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio)methyl]benzoate,
- dd Methyl 3-[[[5-[[[(2-phenylethyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio)methyl]benzoate,
- ee N-[5-[(3-Pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- 30 ff N-[5-[(4-Pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- gg N-(3-Fluorophenyl)-N'-[5-[(2-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- hh N-(3-Fluorophenyl)-N'-[5-[(3-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 35 ii N-(3-Fluorophenyl)-N'-[5-[(4-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- jj 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(2-

- methoxyethyl)acetamide,
- kk 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(2-pyridinylmethyl)acetamide,
- ll 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(4-pyridinylmethyl)acetamide,
- 5 mm N-(2-Phenylethyl)-N'-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- nn N-(2-Phenylethyl)-N'-[5-[(2-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- oo (E)-N-(3-Acetylphenyl)-N'-[5-[(3,7-dimethyl-2,6-octadienyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- 10 pp 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-phenylacetamide,
- qq N-(3-Fluorophenyl)-N'-[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- rr N-[5-[(2-Quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,
- 15 ss 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-2-propenylacetamide,
- tt 2-[[5-[[[(3-Cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]-N-(phenylmethyl)acetamide,
- uu 1,1-Dimethylethyl 5-[[5-[[[(3-(trifluoromethyl)phenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]-2-thiophenecarboxylate,
- 20 vv N-(3-Cyanophenyl)-N'-[5-[[[(1-cyclohexyl-1H-tetrazol-5-yl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- ww 1,1-Dimethylethyl 3-[[5-[[[(3-fluorophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,
- 25 xx 1,1-Dimethylethyl 3-[[5-[[[(3-cyanophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-yl]thio]methyl]benzoate,
- yy N-(3-Cyanophenyl)-N'-[5-[[[1-(3-methylfuro[2,3-c]pyridin-5-yl)ethyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- zz N-(3-Cyanophenyl)-N'-[5-[[[4-(1-methylethyl)-2-pyridinyl]methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 30 aaa N-(3-Fluorophenyl)-N'-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- bbb N-(3-Fluorophenyl)-N'-[5-[(3-furanylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- ccc N-[[5-[(2-Quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]-L-phenylalanine ethyl ester,
- 35 ddd N-[5-[(2-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-[3-(trifluoromethyl)phenyl]urea,

- eee N-[5-[(3-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-(trifluoromethyl)phenyl)urea,
- fff N-[5-[(4-Pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-(trifluoromethyl)phenyl)urea,
- 5 ggg N-(3-Chlorophenyl)-N'-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- hhh N-(3,5-Dichlorophenyl)-N'-[5-[(3-pyridinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- iii N-(3-Cyanophenyl)-N'-[5-[[1-[5-(1-methylethyl)-3-pyridinyl]ethyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 10 jjj N-(3-Fluorophenyl)-N'-[5-[[[5-phenyl-3-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- kkk N-(3-Fluorophenyl)-N'-[5-[[1-(phenylmethyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- lll N-[5-[(Cyclopropylphenylmethyl)thio]-1,3,4-thiadiazol-2-yl]-N'-(3-fluorophenyl)urea,
- 15 mmm N-(3-Fluorophenyl)-N'-[5-[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- nnn N-(3-Fluorophenyl)-N'-[5-[(1-phenylbutyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- ooo N-(3-Fluorophenyl)-N'-[5-[[1-(2-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 20 ppp N-(3-Fluorophenyl)-N'-[5-[[1-(4-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- qqq N-(3-Fluorophenyl)-N'-[5-[[[5-(3-thienyl)-3-pyridinyl)methyl]thio]-1,3,4-thiadiazol-2-yl]urea,
- 25 rrr Ethyl 3-[[[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]benzoate,
- sss 3-[[[5-[(1-Phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]benzoic acid,
- ttt N-(3-Chlorophenyl)-N'-[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]urea,
- 30 uuu Ethyl 3-[[[5-[(2-quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]amino]carbonyl]amino]benzoate,
- vvv N-[5-[(2-Quinolinylmethyl)thio]-1,3,4-thiadiazol-2-yl]-3,5-bis(trifluoromethyl)benzamide,
- www N-[5-[[1-[3-(Acetyl amino)phenyl]ethyl]thio]-1,3,4-thiadiazol-2-yl]-3,4-dichlorobenzamide,
- 35 xxx N-[3-[1-[5-[[[3-Fluorophenyl)amino]carbonyl]amino]-1,3,4-thiadiazol-2-

- yl]thio]ethyl]phenyl]methanesulfonamide,
- yyy N-[5-[[1-(3-Azidophenyl)ethyl]thio]-1,3,4-thiadiazol-2-yl]-N'-(3-fluorophenyl)urea,
- zzz N-[5-[[1-(3-Azidophenyl)ethyl]thio]-1,3,4-thiadiazol-2-yl]-3,4-dichlorobenzamide,
- 5 aaaa 3-Azido-4-chloro-N-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]benzamide,
- bbbb 3-Azido-6-chloro-N-[5-[(1-phenylpropyl)thio]-1,3,4-thiadiazol-2-yl]benzamide,
- cccc 2,6-Difluoro-N-[5-[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]benzamide,
- dddd N-(3-Fluorophenyl)-N'-[5-[[1-(4-fluorophenyl)ethyl]thio]-1,3,4-thiadiazol-2-yl]urea, or
- 10 eeee N-(3-Azido-4-fluorophenyl)-N'-[5-[[1-(3-pyridinyl)propyl]thio]-1,3,4-thiadiazol-2-yl]urea.
3. A method of inhibiting LFA-1 and Mac-1 which comprises administering to a
- 15 patient in need thereof an effective amount of a compound of claim 1.
4. A method of treating a patient suffering from inflammatory diseases which comprises administering to a patient in need thereof an effective amount of a compound of claim 1.
- 20 5. A method of claim 4 wherein the inflammatory diseases are hypersensitivity reactions, asthma, rheumatoid arthritis, bacterial meningitis, aspiration lung injury, inflammatory bowel disorder and related complications.
- 25 6. A pharmaceutical composition which comprises an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D285/12 A61K31/41 C07D417/12 C07D417/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 576 629 A (MORLAND R B ET AL) 18 March 1986 cited in the application see column 1, line 29 - column 2, line 66 ---	1
X	US 3 990 879 A (SOPER Q F) 9 November 1976 see column 2, line 18 - line 39 see column 8 - column 9; examples 18,44 --- -/--	1

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

10 February 1999

Date of mailing of the international search report

19.03.99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fink, D

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 126, no. 16, 21 April 1997 Columbus, Ohio, US; abstract no. 212100c, HUSSEIN A H ET AL: "synthesis of 2-[N-alkyl(aryl)carbamoylamino]-5-alkyl(a) kenyl)thio-1,3,4-thiadiazoles" XP002092279 see abstract & BULG. CHEM. COMMUN. , vol. 28, no. 1, 1995, pages 166-169, ---	1
A	WO 92 08464 A (TANABE SEIYAKU CO) 29 May 1992 see page 38 - page 40; claim 1 see page 5, line 12 - line 23 ---	1,2,6
A	CHEMICAL ABSTRACTS, vol. 090, no. 13, 26 March 1979 Columbus, Ohio, US; abstract no. 103925t, RUSSO F ET AL: "Synthesis of 2,6-substituted derivatives of 5H-1,3,4-thiadiazolo[3,2-a]-s-triazine-5,7 -dione" XP002092282 see abstract & FARMACO, ED. SCI. , vol. 33, no. 12, 1978, pages 972-983, ---	1,2,6
A	EP 0 449 211 A (WARNER LAMBERT CO) 2 October 1991 see page 37 - page 38; claim 1 see page 32; example 38 see page 2, line 24 - line 35 ---	1,2,6
A	EP 0 371 438 A (WARNER LAMBERT CO) 6 June 1990 see page 57 - page 59; claim 1 see page 38; example 27 see page 4, line 18 - line 23 -----	1,2,6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 98/21630

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 3-5 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4576629 A	18-03-1986	NONE	
US 3990879 A	09-11-1976	NONE	
WO 9208464 A	29-05-1992	NONE	
EP 0449211 A	02-10-1991	US 5102897 A JP 4221373 A	07-04-1992 11-08-1992
EP 0371438 A	06-06-1990	AT 127116 T AU 631385 B AU 4562589 A CA 2004154 A,C DE 68924044 D DE 68924044 T DK 599789 A ES 2075845 T FI 93954 B GR 3017688 T IE 68850 B JP 2270865 A JP 2821208 B KR 9704914 B NO 178623 B PT 92451 A,B US 5376670 A US 5155122 A US 5256680 A PH 27025 A	15-09-1995 26-11-1992 21-06-1990 29-05-1990 05-10-1995 15-02-1996 30-05-1990 16-10-1995 15-03-1995 31-01-1996 24-07-1996 05-11-1990 05-11-1998 08-04-1997 22-01-1996 31-05-1990 27-12-1994 13-10-1992 26-10-1993 01-02-1993